Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$4.77 USD
-0.12 (-2.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.82 +0.05 (1.05%) 7:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Champions Oncology, Inc falls in the month of April.
All items in Millions except Per Share data.
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 10 | 9 | 5 | 8 |
Receivables | 10 | 8 | 10 | 7 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 0 |
Total Current Assets | 14 | 19 | 20 | 13 | 14 |
Net Property & Equipment | 6 | 7 | 7 | 6 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 26 | 34 | 35 | 28 | 21 |
Liabilities & Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 3 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 2 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 13 | 11 | 6 | 6 |
Total Current Liabilities | 22 | 22 | 17 | 11 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 30 | 26 | 20 | 15 |
Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 83 | 82 | 81 | 80 | 78 |
Retained Earnings | -85 | -77 | -72 | -73 | -73 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -2 | 5 | 9 | 7 | 5 |
Total Liabilities & Shareholder's Equity | 26 | 34 | 35 | 28 | 21 |
Total Common Equity | -2 | 5 | 9 | 7 | 5 |
Shares Outstanding | 13.50 | 13.50 | 13.50 | 13.30 | 11.80 |
Book Value Per Share | -0.14 | 0.34 | 0.67 | 0.56 | 0.45 |
Fiscal Year End for Champions Oncology, Inc falls in the month of April.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 3 | 4 | 6 | 5 |
Receivables | NA | 10 | 8 | 8 | 9 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 1 | 1 | 1 |
Total Current Assets | NA | 14 | 13 | 14 | 15 |
Net Property & Equipment | NA | 6 | 7 | 7 | 7 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 26 | 27 | 28 | 30 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 5 | 5 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 13 | 13 | 11 |
Total Current Liabilities | NA | 22 | 22 | 21 | 20 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 28 | 29 | 28 | 28 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 83 | 83 | 83 | 82 |
Retained Earnings | NA | -85 | -84 | -82 | -80 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | NA | -2 | -2 | 0 | 2 |
Total Liabilities & Shareholder's Equity | NA | 26 | 27 | 28 | 30 |
Total Common Equity | 0 | -2 | -2 | 0 | 2 |
Shares Outstanding | 13.50 | 13.50 | 13.50 | 13.40 | 13.40 |
Book Value Per Share | 0.00 | -0.14 | -0.15 | 0.01 | 0.14 |